Singleron Completes Series B Financing, Raising Close to $100M
Singleron Biotechnologies, an innovative biotech company dedicated to applying groundbreaking single cell multi-omics technologies to clinical applications, drug development, and health management, recently completed its oversubscribed Series B financing, raising close to $100M. New investors include Lake Bleu Capital, Firstred Capital and MSA Capital, joined by existing investors Sherpa Healthcare Partners, Lilly Asia Ventures (LAV), ARCH Venture Partners, CDG Capital, CDH Investments, Superstring Capital, 3w Global Investment, and SBCVC.
Founded in 2018, Singleron develops and commercializes single cell multi-omics products that can be used in both research and clinical settings. Its current product portfolio includes instruments, microfluidic systems, reagents, software solutions, and database that facilitate high-throughput single cell multi-omics analysis. The company currently has offices, laboratories, and manufacturing facilities in China, Germany, and the US. Its products are already serving over 1000 laboratories in hospitals, research institutes, and pharmaceutical companies. Singleron will invest the proceeds from this round of financing to further speed up the development of its single-cell platform products, to obtain regulatory approval for in vitro diagnostics products based on its single cell technologies; and to ramp up its international presence.
About Lake Bleu Capital:
Based in Hong Kong and Shanghai, Lake Bleu Capital (www.lakebleu-cap.com) is a multi-billion investment platform focused on healthcare space. Lake Bleu Capital’s USD public equity fund is one of the largest healthcare specialist funds in Asia. Thanks to its outstanding performance since inception, the fund has been awarded as the sole winner of the “5 Year Award: Over 500m category” by AsiaHedge in 2020 and the “Best Asia ex-Japan Fund” by industry authorities multiple times in recent years. Lake Bleu Capital is also active in mid-to late-stage private equity investment in China’s healthcare sector. It has successfully invested in over 50 high quality private companies and provided the invested companies with strategic value- add services while growing with the companies in the long run.
About Firstred Capital:
Firstred Capital is a private equity firm founded in 2019 by Ms. Xiaodan Liu. It has AUM over 10bn RMB and focuses on growth and buyout opportunities in consumer, healthcare, technology and industrial sectors. The core members of Firstred Capital include domestic and international industry veterans, with extensive onshore and cross-border M&A and investment experiences. Leveraging its insight into industrial evolution and understanding of capital markets, and through partnership with industry leaders and preeminent management teams, Firstred is committed to support the sustainable growth of portfolio companies and create long-term economic and social value.
About MSA Capital:
Founded in 2014, MSA Capital is an independent global private equity and venture capital firm with over $1.7 billion under management. The firm manages capital from the world's top sovereign wealth funds, international asset managers, pension funds, university endowments, fund of funds and family offices, as well as China's leading new economy entrepreneurs.
MSA actively partners with outstanding entrepreneurs in China and other technology markets to build leading, innovative companies that aim to deliver strong financial returns and meaningful, positive impact. The firm is headquartered in Beijing, with resident teams in Shanghai, Hong Kong, Singapore, Middle East, North Africa and the United States.